18
Participants
Start Date
February 19, 2019
Primary Completion Date
May 19, 2030
Study Completion Date
June 19, 2044
iC9.GD2.CAR.IL-15 T-cells
Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
Cyclophosphamide
500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
Fludarabine
30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
WITHDRAWN
Emory - Winship Cancer Institute, Atlanta
RECRUITING
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Collaborators (1)
UNC Lineberger Comprehensive Cancer Center
OTHER
United States Department of Defense
FED
Bellicum Pharmaceuticals
INDUSTRY
National Cancer Institute (NCI)
NIH